DBVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as DBVTF

DBV Technologies S.A.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 16, 2026

$8.97−0.08 (-0.88%)

Close on Oct 19, 2026

Market cap: $3.89B
P/E (TTM): –
Dividend yield: –

DBV Technologies S.A. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31	Q3 2022 2022-09-30	Q2 2022 2022-06-30	Q1 2022 2022-03-31	Q4 2021 2021-12-31	Q3 2021 2021-09-30	Q2 2021 2021-06-30	Q1 2021 2021-03-31	Q4 2020 2020-12-31	Q3 2020 2020-09-30	Q2 2020 2020-06-30	Q1 2020 2020-03-31
Stock-Based Compensation	3.70	2.30	1.92	0.52	1.20	1.70	-0.45	1.59	1.53	1.96	1.22	1.35	-1.81	-1.81	1.61	-0.98	-1.08	1.36	-0.96	-1.55	-1.09	1.43	1.84	0.07	5.96	3.07
Other Non-Cash Items	-0.10	0	1.23	-0.01	-0.50	-0.50	0.67	-0.64	-0.04	0.01	0	0	-0.02	0	0.00	0	0	0.00	0.56	-2.06	0.39	0.46	0.13	-0.41	0.04	-0.42
Change in Accounts Receivable	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	0	0	-0.02	0.00	0.07	2.10	-0.10	-1.98	–	–
Change in Inventory	-2.60	-3.00	–	–	-6.00	-4.30	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.04	3.73	0.97	-2.40
Change in Accounts Payable	0.10	-0.50	1.50	-0.62	4.00	11	1.36	1.96	1.76	-4.81	6.73	-1.73	-1.06	4.48	-2.24	-0.20	5.91	-0.02	-0.42	-3.97	-0.60	-2.57	1.68	-8.45	4.90	-3.21
Operating Cash Flow	-53	-49	-35	-32	-34	-20	-12	-22	-35	-35	-14	-20	-26	-21	-24	-20	-10	-1.48	-19	-23	-30	-36	-34	-42	-40	-50
Capital Expenditures	-0.40	-0.40	-0.37	-0.16	0	0	0.13	-0.40	-0.73	-1.34	-0.35	-0.05	-0.16	-0.11	-0.01	-0.37	-0.24	-0.13	-0.91	0.01	0.17	-0.18	–	–	-0.62	-0.82
Sale of Property, Plant & Equipment	–	–	–	–	–	–	–	0	0	0	0	0	0	0	0.01	0	0	0.00	0.56	0.05	0	0	–	–	–	–
Purchase of Investments	–	–	–	–	–	–	0.17	-0.17	0.86	-0.86	0.05	-0.03	-0.03	0	0.03	0.13	-0.24	-0.04	-0.12	0	0.00	0.00	–	–	–	–
Investing Cash Flow	-0.60	-0.30	-0.72	-0.25	0	-0.40	0.79	-0.11	0.69	-2.13	-0.19	-0.32	-0.34	0.04	-0.03	0.15	-0.23	0.01	-0.47	0.05	0.17	-0.19	-0.63	-0.78	-0.52	-0.93
Stock Issued	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	0	150	–	–	–	–
Other Financing Activities	–	–	–	–	–	–	–	–	–	–	0	0	–	–	0	0	0	0	0.01	0.00	0	-0.02	-0.01	-0.01	-0.01	-0.01
Financing Cash Flow	0.10	89	159	0.12	117	0	0.68	0.01	-0.03	-0.06	-0.19	-0.84	7.81	-0.01	-0.28	-0.82	195	-0.13	0.38	-1.17	0.63	0.44	-0.08	-1.05	0.06	151
Foreign Exchange Rate Adjustments	-1.10	-4.50	1.16	-0.78	7.20	0.50	-3.20	2.79	-0.90	-2.96	6.29	-4.10	-0.24	3.91	21	-15	-11	-1.59	-2.01	-3.22	2.52	-7.94	9.19	13	6.10	-5.81
Net Change in Cash	-54	35	124	-33	90	-20	-14	-20	-35	-40	-7.77	-25	-18	-17	-3.48	-35	174	-3.19	-21	-27	-27	-44	-25	-32	-35	94
Free Cash Flow	-53	-50	-36	-33	-34	-20	-12	-23	-36	-36	-14	-20	-26	-21	-24	-20	-10	-1.61	-20	-23	-30	-36	–	–	-41	-50

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -3543.1%
Net margin: -3506.5%
Return on equity, FY2025: -149.8%

Financial strength

Current ratio: 3.72
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 322.1%

Valuation

P/E ratio: –
Price to sales: 774.82
Price to book: 24.24
Dividend yield: –